Related Experiment Video

Updated: Sep 28, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.9K

Comprehensive genomics in androgen receptor-dependent castration-resistant prostate cancer identifies an adaptation

Yuki Makino1, Yuki Kamiyama1, J B Brown2,3

  • 1Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.

Communications Biology
|April 2, 2022
PubMed

Insights

Researchers identified OPRK1 as a key player in castration-resistant prostate cancer (CRPC) progression. Targeting OPRK1 may offer new therapeutic strategies for this lethal disease.

Area of Science:

  • Oncology
  • Genomics
  • Molecular Biology

Background:

  • Castration resistance is a lethal treatment failure in prostate cancer (PCa), characterized by androgen receptor (AR) activation independent of ligands.
  • The mechanisms by which AR promotes PCa survival and growth during androgen deprivation are not fully understood.

Purpose of the Study:

  • To investigate the genomic mechanisms underlying acquired, androgen receptor-dependent castration-resistant prostate cancer (CRPC).
  • To identify novel therapeutic targets for CRPC by analyzing AR binding and gene expression in a patient-derived xenograft model.

Main Methods:

  • Utilized a patient-derived xenograft model of acquired, AR-dependent CRPC.
  • Performed integrative genomics, including AR chromatin immunoprecipitation sequencing (AR-ChIP-seq).
  • Conducted in vitro and in vivo functional studies and immunohistochemical analysis of human PCa tissues.

Main Results:

  • AR binding site (ARBS) profiles in xenograft models differed from previously reported data.
  • Identified OPRK1 as an AR-target gene upregulated during androgen deprivation and associated with CRPC progression.
  • OPRK1 loss of function inhibited CRPC growth, and OPRK1 expression was elevated in human CRPC tissues.

Conclusions:

  • OPRK1 is implicated in post-castration survival and adaptation during PCa progression to castration resistance.
  • OPRK1 represents a potential therapeutic target for managing lethal prostate cancer.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K
Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

11.3K

Related Concept Videos

Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
2.2K
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
851
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.7K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.9K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.0K